



Sessie 11 Personalised Medicine: visie en ontwikkelingen

Progr.	Dossierr	Titel	Projectleider/ instelling	Einddatum
OR1	836011009	Treatment of patients with Fabry disease with agalsidase alfa and agalsidase beta: phenotypic diversity necessitates the development of individualized treatment guidelines.	C.E.M. Hollak / AMC	1-2-2016
OR1	836021019	The Netherlands Breast Cancer Project (NBCP): Towards personalized medicine by using the nationwide population-based breast cancer registry (1989-2011) coupled with biobanking.	Prof. dr. S.C. Linn	1-12-2016
OR1	836031008	Optimalization of Eculizumab/Soliris® treatment in patients with atypical hemolytic uremic syndrome by means of individually-tailored, personalized therapy.	Dr. N.C.A.J. van de Kar	1-3-2017
RR	836001005	Het ontwikkelen van een nationale database voor het gebruik van biologicals en andere systemische medicatie bij patiënten met matig-ernstige tot ernstige psoriasis.	Dr. J.J.E. van Everdingen / Nederlandse Vereniging voor Dermatologie en Venereologie	1-6-2013
RR	836002002	Implementatie medicamenteuze behandeling van gemetastaseerd melanoom in Nederland	Dr. ir. J.J.M. van der Hoeven / MCA	31-4-2014
DOof	94501015	Shorter treatment duration of endocarditis based on C-reactive protein values	prof dr. P. Speelman,	1-1-2004
DOf	94502029	Arthroscopy to predict the response to TNF-a blockade	Prof. dr. P.P. Tak,	1-7-2005
DOf	94527015	Monitoring of exhaled nitric oxide (FENO) to tailor the lowest effective dose of oral corticosteroids in severe asthma (MONOSA-Study)	Dr. E.H.D. Bel	1-3-2009
OR1	836011001	Shortcomings in guidelines: parameters for initiating anti-TNF in inflammatory bowel disease patients: the development of an anti-TNF decision model.	C.J. van der Woude / Erasmus MC	1-4-2015
OR1	836021007	Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients.	Dr. P. Denig	1-10-2016
OR4	836041005	Introduction of a biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis	Prof. dr. N.M. Wulffraat Arts	1-1-2019
DOf	1708856019	The value of information in the evaluation of diagnostic and screening tests	Dr. B.C. Opmeer	1-1-2011